Sentences with phrase «of sofosbuvir»

«The discovery of sofosbuvir was a team effort, and I am honored and humbled to be receiving this recognition,» Sofia said.

In subsequent tests using an immunodeficient mouse model infected by Zika, intravenous injections of sofosbuvir significantly reduced viral loads in blood serum compared to a placebo group.

Since then, Gilead has run three additional studies of sofosbuvir paired with a different drug, ledipasvir.

In a more advanced trial, 12 weeks of sofosbuvir plus ribavirin yielded the same results as 24 weeks of interferon plus ribavirin: 67 percent of patients had no evidence of the virus in their blood (although side effects such as fever and depression were fewer among patients who did not receive interferon).

Another paper in the same edition of the NEJM reports two additional studies of sofosbuvir - containing therapy, one evaluating a 12 week regimen of peginterferon, ribavirin and sofosbuvir in patients with genotypes 1, 4, 5 and 6 who have never been treated before; the other reporting results of a trial comparing 24 weeks of peginterferon and ribavin with 12 weeks of sofosbuvir and ribavirin in treatment naïve patients with genotypes 2 and 3.

«The results of the ION studies demonstrated highly satisfactory cure rates with a fixed dose combination of sofosbuvir / ledipasvir among patients with genotype 1 HCV infection without the use of either injectable interferon, which causes miserable flu - like symptoms, or ribavirin, an antiviral pill associated with a variety of troublesome side effects, including anemia and rash,» Professor Peck - Radosavljevic continued.

Results presented today at The International Liver Congress ™ 2015 demonstrate that hepatitis C (HCV)- infected genotype - 3 (GT - 3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

Not exact matches

Thanks to a number of new Hepatitis C drugs (Sofosbuvir Ledipasvir, Ladispavir) the disease is curable for many patients.

This study highlights that sofosbuvir with ribavirin and peginterferon should be considered for interferon - eligible GT - 3 patients, particularly for those with cirrhosis and / or prior treatment failure,» said Graham Foster, Professor of Hepatology, Queen Marys University of London, UK.

It has confirmed that 24 weeks is the optimal duration for a sofosbuvir and ribavirin combination in GT - 3 patients, whilst also finding that sofosbuvir and ribavirin with peginterferon for 12 weeks resulted in the highest SVR12 rates observed to date in a Phase 3 study,» said Professor Tom Hemming Karlsen, Scientific Committee Member, European Association for the Study of the Liver (EASL).

The current standard of care for HCV genotype 3 is the nucleotide polymerase inhibitor sofosbuvir with weight - based RBV for 24 weeks.

Sofosbuvir can cost up to $ 55,000 for a course of treatment.

The most common restrictions fall into three categories: 1) The level of fibrosis (i.e., scarring of the liver); 2) substance use and abstinence from alcohol / drug use together with toxicology screening; and 3) provider limitations, which limit the physicians allowed to prescribe sofosbuvir.

«In distinct contrast to the situation in the U.S., Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recently recommended two highly effective sofosbuvir - based regimens for Pharmaceutical Benefits Scheme (PBS) listing, without drug use or disease stage - related restrictions,» said co-author and professor Greg Dore of the Kirby Institute.

Taylor's research team, which included the Harvard Law School Center for Health Law and Policy Innovation, Treatment Action Group, Kirby Institute of Australia, and Brown University, found that most Medicaid coverage restrictions for sofosbuvir violate federal Medicaid law, which requires states to cover drugs consistent with their U.S. Food and Drug Administration (FDA) labels.

Taylor's team of researchers examined Medicaid policies for hepatitis C virus treatment using sofosbuvir, more commonly known as Solvadi, and found that most should change policy to improve access to the treatment.

In September 2017, the government of Malaysia issued a «government - use» license on sofosbuvir patents to allow 400,000 people living with hepatitis C in Malaysia to access generic HCV regimens in public hospitals.

«Given the absence to date of alternative therapies for patients with genotype 2 or 3 who have failed interferon therapy or for whom it is not an option, treatment with the new sofosbuvir regimen offers a vast improvement,» Dr. Jacobson says.

The drug sofosbuvir works by interfering with the ability of the hepatitis C virus to replicate.

301 chronically infected adults were treated with the ravidasvir / sofosbuvir combination for 12 weeks for patients without cirrhosis of the liver, and for 24 weeks for those with compensated cirrhosis.

Results from three Phase III clinical trials (ION - 1, ION - 2 and ION - 3) evaluating the investigational once - daily fixed - dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and the NS5A inhibitor ledipasvir (LDV) 90 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver CongressTM 2014.

«The new sofosbuvir therapy offers a much - needed alternative to standard therapy with interferon, which can cause significant side effects for hepatitis C patients,» says the study's lead investigator, Dr. Ira Jacobson, chief of the Division of Gastroenterology and Hepatology and Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medical College.

Most states violate federal Medicaid law because they deny coverage for sofosbuvir, a new and highly effective treatment to cure hepatitis C, according to Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV / Viral Hepatitis Coinfection Program.

«Ledipasvir plus sofosbuvir: Hint of added benefit in further patient group.»

The recent release of drugs such as sofosbuvir has marked the first successful and nontoxic treatments for hepatitis C — treatments which came directly from the work of Bartenschlager, Rice, and Sofia.

«The cohort study has found that the sofosbuvir / daclatasvir combination is associated with a high rate of SVR4 in difficult - to - treat patients infected by genotype - 1 hepatitis C.

Six months prior, the U.S. Food & Drug Administration (FDA) approved sofosbuvir, an oral medication shown to cure most cases of hepatitis C infection, with fewer side effects than the current treatment options.

This is one of the first real - life studies looking into sofosbuvir / daclatasvir combinations and has demonstrated that this is a good therapeutic option for these patients.

A study presented today that evaluated an investigational dosage of once - daily ledipasvir 45 mg / sofosbuvir 200 mg (LDV / SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99 % of children (n = 89/90) had undetectable levels of HCV - RNA 12 weeks after treatment.

During sofosbuvir's development, they had studied other drugs that inhibited different viral proteins and that might eliminate the need for continued use of interferon and ribavirin.

In Egypt, which has the world's highest rate of hepatitis C, sofosbuvir costs $ 300 for a 28 - day supply.

Notably pricey members of the influential list include sofosbuvir for HCV and the antileukemia drug Gleevec.

For example, sofosbuvir's manufacturer, Gilead Sciences Inc. of Foster City, California, sells the drug to Egypt at a discount and allows generic manufacturers in India to produce and sell in 91 poorer countries.

Moreover, fetuses of Zika - infected pregnant mice did not show detectable Zika virus amplification in the sofosbuvir - treated group.

The drug works by inhibiting replication of the hepatitis C virus; researchers noted that both hepatitis C and Zika belong to the same viral family and bore strong structural similarities that could make sofosbuvir effective against the latter.

Using sofosbuvir - ledipasvir, which is sold as Harvoni, and is one several new drugs for hepatitis C, researchers compared the costs of treating patients at all stages of fibrosis, zero through four, with the cost of waiting until stages three or four, which is when some patients are usually treated.

As part of a compassionate use program, 104 post-liver transplant patients with recurring HCV who had exhausted all treatment options and had poor clinical prognoses, received sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) included at the physicians» discretion for up to 48 weeks.

The higher cure rate and lessened side - effects of treating patients with an all - oral combination of ledipasvir and sofosbuvir (LDV / SOF) results in greatly reduced absenteeism and improved workplace productivity that can translate into enormous benefit, according to the new economic model used by researchers at Inova Fairfax Medical Campus, VA..

Sofia will receive the 2016 Lasker - DeBakey Award on Sept. 23 along with Charles Rice, Ph.D., of Rockefeller University and Ralf Bartenschlager, Ph.D., of Heidelberg University, who were recognized for their work in developing systems essential to hepatitis C research, which Sofia used in developing the drug, sofosbuvir.

Today, with just 12 weeks of treatment with drug combinations that use Sofia's drug, sofosbuvir (Sovaldi ®) as the backbone of Harvoni ®, almost all those treated are cured.

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options; David R. Nelson, MD, University of Florida.

The ledipasvir / sofosbuvir combination, Harvoni ®, is now FDA - approved for numerous types of HCV infection, including the most common form in the US and Europe.

The drugs — Olysio (simeprevir) and Solvadi (sofosbuvir)-- cure up to 80 % of cases.

Examples of DAAs, which come in pill form, are Olysio (simeprevir); Sovaldi (sofosbuvir), which is used in combination with Olysio; Daklinza (daclatasvir); and Harvoni (a combination of ledipasvir and sofosbuvir).